RxDoctor Payments Data

Sara Wiles

Family · Germantown, TNNPI 1629431226

Payments from drug & device makers

$1,107in general payments, 2019–2025

Across 12 payments — averaging $92.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$431
  • Abbott$148
  • Penumbra, Inc.$131
  • Chiesi USA, Inc.$122
  • Heartflow, Inc.$107
  • AstraZeneca$78
  • plus $91 from 2 others

What the payments were for

  • Food & beverage$1,107100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen4$431
Abbott1$148
Penumbra, Inc.1$131
Chiesi USA, Inc.1$122
Heartflow, Inc.1$107
AstraZeneca1$78
Merck2$77
AbbVie1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,107 in reported general payments places this provider in the 65th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$53,027
Medicare patients
526
Services billed
1,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan113$125,896
Repatha SureclickEvolocumab110$119,155
EliquisApixaban77$71,366
FarxigaDapagliflozin Propanediol58$67,961
JardianceEmpagliflozin25$35,452
Praluent PenAlirocumab37$30,752
Repatha SyringeEvolocumab32$30,230
XareltoRivaroxaban17$16,765
BrilintaTicagrelor11$8,335
Ezetimibe152$3,626
Atorvastatin Calcium148$1,321
Rosuvastatin Calcium114$1,188
Metoprolol Succinate113$1,184
Terazosin Hcl80$1,112
Hydralazine Hcl81$1,004

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$78$76,29669 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,706 family providers in Tennessee.

Other family in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →